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Abstract
Objective: With the increasing burden of heart failure (HF) in the Middle East Region and Africa (MEA), it is
imperative to shift the focus to prevention and early detection of cardiovascular diseases. We present a broad consensus
of the real-world challenges and strategic recommendations for optimising HF care in the MEA region.
Method: To bridge the gaps in awareness, prevention, and diagnosis of HF, an assembly of experts from MEA shared
their collective opinions on the urgent unmet needs.
Results: Lack of awareness in the community, high prevalence of risk factors, poor accessibility and affordability of
care and diagnostics are the major barriers for delayed or missed diagnosis of HF in MEA. Enhancing patient awareness,
through digital or social media campaigns, alongside raising knowledge of healthcare providers and policymakers with
training programmes, can pave the way for inﬂuencing policy decisions and implementation of robust HF programmes.
Multicountry registries can foster development of guidelines factoring in local challenges and roadblocks for HF care.
Region-speciﬁc guidelines including simpliﬁed diagnostic algorithms can provide a blueprint of care for early detection
of at-risk patients and facilitate efﬁcient referral, thus mitigating clinician “therapeutic inertia.” Multidisciplinary care
teams and HF clinics with expanded role of nurses can streamline lifestyle modiﬁcation and optimum control of dyslipidaemia, blood pressure, and glycaemia through guideline-recommended prevention therapies such as sodiumglucose co-transporter-2 inhibitorsdthus supporting pleiotropic effects in high-risk populations.
Conclusion: Development of regional guidelines, enhancing awareness, leveraging digital technology, and commitment for adequate funding and reimbursement is pivotal for overcoming structural and health system-related barriers in
the MEA region.
Keywords: Heart failure, Middle East region and Africa, Awareness, Prevention, Diagnosis, Diabetes
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1. Introduction

H

eart failure (HF) is a multifaceted clinical
syndrome
with
numerous
aetiologies
including, but not limited to, coronary artery disease, previous myocardial infarction, hypertension,
valvular heart disease, cardiomyopathy, rheumatic
heart disease and diabetes. HF with reduced ejection fraction (HFrEF) (left ventricular ejection fraction [LVEF] <40%) is inﬂuenced by diverse genetic,
environmental risk factors, and comorbidities. With
a global prevalence of 64.34 million cases and 9.91
million years lost due to disability, HF has a 1-year
mortality rate of 17.4% in acute HF and 7.2% in
chronic stable HF [1,2]. About 17%e45% of patients
admitted in hospital with HF die within one year of
admission, thus HF has worse survival outcomes
compared to common cancers such as prostate and
breast [3,4]. The International Congestive Heart
Failure (INTER-CHF) cohort study reported a 1-year
mortality rate of 16$5%d highest in Africa (34%)
and India (23%), and lowest in China (7%), South
America (9%), and the Middle East (9%) [5].
Approximately 1 in 5 people in general population
after 40 years of age is expected to develop HF at
some point in their lifetime [6]. The linear relationship between socio-demographic index and HF
mortality foretell an enhanced risk for low- and
middle-income countries [7]. The wide variations in
epidemiology, risk factors, clinical interventions,
and availability of resources across geographies
warrant better insights into the region-speciﬁc
practices for HFd to understand the determinants
and precipitants in terms of patient outcomes.
Although HF management is a common unmet
need for the Middle East Region and Africa (MEA),
diverse socioeconomic strata in this population may
lead to region-speciﬁc limitations and unmet needs.
To identify the current gaps and unmet needs for
HF care in the MEA region, a multidisciplinary
meeting with experts from different countries across
the region was convened. The panel aimed to gain
insights on the real-world challenges in HF awareness, prevention and diagnosis, and contribute region-speciﬁc
strategic
recommendations
for
optimising HF care and enhancing patient support.

2. Consensus methodology
The MEA steering committee meeting held on 05
December 2020 included a team of 14 members with
expertise in the management of HF across the MEA
region (Kenya [n ¼ 1], South Africa [n ¼ 1], Egypt
[n ¼ 2], Iraq [n ¼ 1], Jordan [n ¼ 1], Kuwait [n ¼ 1],
Lebanon [n ¼ 1], Morocco [n ¼ 1], Saudi Arabia

List of abbreviations
ESC-HF-LT

European Society of Cardiology Heart
Failure Long-Term Registry
HEARTS Heart function assessment registry trial
HF
Heart failure
HFrEF
Heart failure with reduced ejection fraction
HFmrEF HF with midrange ejection fraction
HFpEF HF with preserved ejection fraction
INTER-CHF
International Congestive Heart Failure
MACE Major adverse cardiovascular events
MEA
Middle East Region and Africa
MENA Middle East and North Africa
NICE
National Institute for Health and Care Excellence
NT proBNP
N-terminal pro b -type natriuretic
peptide
NYHA New York Heart Association
PEACE Program for the Evaluation and Management of
the Cardiac Events
SPRINT Systolic Blood Pressure Intervention Trial
SSA
Sub-Saharan Africa
WATCH-DM
(Weight [body mass index], Age, hypertension, Creatinine, high density lipoprotein cholesterol, Diabetes control
[fasting plasma glucose], QRS Duration,
myocardial infarction, and Coronary
Artery Bypass Grafting)

[n ¼ 2], Turkey [n ¼ 2] and United Arab Emirates
[UAE] [n ¼ 1]) (Fig. 1).
The moderator-led sessions encompassed a
comprehensive presentation of the current and future
perspectives of HF in the MEA countries, followed by
a discussion wherein the experts individually shed
light on region-speciﬁc challenges in HF screening,
diagnosis and management. The gap analyses was
followed by a brainstorming session where the experts then presented possible solutions and suggested
strategic recommendations, based on their experience
in the HF arena. These responses were assimilated
and a thematic analyses was performed to precisely
categorise the region-speciﬁc recommendations.

3. Burden of heart failure in MEA
The age-standardised prevalence rates (per
100 000) of HF for MEA (972.3) are relatively higher
compared to the global average (831.0) and other
developed countries from Western Europe (811.7)
and Southeast Asia (655.0) [8] (Table 1). Gulf CARE
registry, including seven Middle Eastern countries,
reported that 59% of the patients had HFrEF, 21%
had HF with midrange ejection fraction (HFmrEF,
LVEF 40%e50%) and 20% had HF with preserved
ejection fraction (HFpEF, LVEF >50%) [9]. Underrepresentation of HFpEF (<30%) of the whole population of HF is reported in MEA region [10,11].
There are wide inter- and intra-regional disparities
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Fig. 1. Process of steering committee meeting for consensus methodology. HF¼Heart failure; MEA ¼ Middle East Region and Africa.

in patient characteristics and aetiology in the MEA
region, particularly in the Sub-Saharan Africa (SSA)
(including South Africa). The average age of affected
individuals in this population is at least ten years
younger than their Western counterpartsdpartly
explaining the reason for lower prevalence of
HFpEF. The mean age of HF patients is lowest in
SSA (52 years), and Africa (53 years), followed by
Middle East (56.4 years), North Africa (58.79 years),
Asia (60 years) and Europe (70 years) [12e15]. Risk
factors such as diabetes mellitus, obesity, smoking
and socioeconomic transition, marked by increasing
levels of sedentary life, lack of physical activities and
increase in consumption of fatty foods contribute to
the higher prevalence of HF in the MEA region [16].
In addition, people from Africa are more likely to
lack health insurance and have severe symptoms
with New York Heart Association (NYHA) functional classiﬁcation class IV. The most common HF
Table 1. Age-standardized prevalence rates (per 100 000) for heart
failure.
Region

Age-standardized Prevalence
Rates (per 100 000)

Global
Western Europe
North America
Southeast Asia
North Africa and Middle East
Egypt
Morocco
Kuwait
Lebanon
Saudi Arabia
Turkey
United Arab Emirates
Sub-Saharan Africa
Eastern
Central
Southern
Western

831.0 (738.6e926.2)
811.7 (726.2e908.6)
956.1 (895.8e1021.5)
655.0 (573.4e743.8)
972.3 (861.6e1091.6)
1030.8 (892.2e1199.2)
984.2 (854.1e1132.6)
1178.0 (1026.7e1343.3)
1027.9 (892.6e1180.1)
1016.9 (885.0e1153.0)
946.0 (865.6e1035.3)
1047.8 (905.8e1200.2)
700.0
675.0
761.7
708.7

(614.4e796.8)
(592.2e775.8)
(668.9e863.8)
(621.4e805.9)

Global Burden of Disease study 2017 (Bragazzi et al., 2021).

aetiology was hypertensive heart disease in Africa
(including SSA) and ischaemic cardiomyopathy in
the Middle East [13].
HF is accompanied with signiﬁcant morbidity and
mortality, and it considerably impacts patients’
health-related quality of life [4]. Prospective data
from the European Society of Cardiology Heart
Failure Long-Term Registry (ESC-HF-LT) reported
signiﬁcant between-region differences in 1-year HF
outcomes, these being attributable to differences in
medical practices, available resources, and health
system structure. Per the ESC-HF-LT, cardiovascular related mortality rates among chronic HF in
different European regions were as follows: Eastern
(38.7%; N ¼ 1335), Middle-East (23.3%; N ¼ 289),
Northern (65.3%; N ¼ 435), North Africa (41.1%;
N ¼ 468), Southern (54.2%; N ¼ 4321), Western
(71.4%; N ¼ 553), Total (49.8%; N ¼ 7401) [17]. In the
INTER-CHF study, the age-adjusted mortality was
worse in SSA compared to other low- and middleincome regions [13]. The Gulf CARE registry reported in-hospital mortality rate of 5.2%, 12-month
cumulative mortality rate of 8.8% and 12-month rehospitalisation rate of 28% [9]. HF incurs substantial
economic burden in the MEA region (total estimated costs is US $ 1.92 Billion), with inpatient
admission being the major cost driver [18]. Notably
recurrent hospitalisations account for the predominant economic burden of HF [19].
We present herein, the gaps and unmet needs,
potential recommendations, and the way forward
for enhanced prevention and diagnosis of HF in
MEA region.

4. Gaps and recommendations for awareness
and prevention of heart failure
The experts discussed that the lack of awareness in
community, high prevalence of primary factors such
as hypertension, diabetes, and in some areas
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coronary artery disease, compounded by poor
accessibility and affordability of healthcare, are major
patient-related barriers for prevention of HF in the
MEA region (Fig. 2). Lack of robust regional databases or registries and under-representation of MEA
region in research studies are barriers for identifying
the real-world burden of HF, hindering prevention
strategies. In addition, the high prevalence of existing
infectious diseases such as tuberculosis and human
immunodeﬁciency virus in some countries shift the
focus from non-communicable disease like cardiovascular diseasedleading to a lack in momentum
and economic support for implementation of HF
awareness programmes and campaigns. Paucity of
region-speciﬁc HF guidelines that would provide a
blueprint of care and scarcity of speciﬁcally trained
HF care workers has a negative impact on doctor and
health funder awareness. This reduces the region's
ability for early detection of patients at risk during
their HF journey. Furthermore, political instability,
difﬁculty in resource management (including
manpower and medications), poor awareness among
the medical community about HFpEF, and lack of
patient support were cited as negative attributes
hindering HF care in MEA region.
The experts recommended that it is imperative to
focus on healthy life style, recognition and

treatment of risks for ischaemic heart disease and
hypertension, alongside optimal management of
diabetes, obesity, and hyperlipidaemia for stage A
HF, and timely diagnosis and treatment of asymptomatic left ventricular dysfunction for Stage B HF.
Community/media guided social media campaigns
and outreach programmes can pave the way for
enhanced patient awareness regarding preventive
strategiesdand subsequently inﬂuence policy decisions for implementation and funding of HF programmes. Similarly, formulation of local HF
societies focussing on training healthcare professionals (including nurses and pharmacists)
should be encouraged. Formal HF societies would
ensure wide dissemination of national HF management guidelines for increasing physician awareness
and compliance to guideline-directed medication.
HF therapy involves multiple drugs and often
complex up-titrations; thus, local HF guidelines
would be a major force in overcoming clinician
“therapeutic inertia”. The panel highlighted the
need for utilisation and reimbursement of drugs
targeted at primary prevention of HF, such as sodium-glucose co-transporter-2 inhibitors in “at risk”
type 2 diabetes mellitus) individuals, alongside
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and beta blockers in

Fig. 2. Root cause analysis illustrating the multifaceted characteristics of heart failure. HF ¼ heart failure; HIV ¼ human immunodeﬁciency virus;
HT ¼ hypertension; MEA ¼ Middle East region and Africa; TB ¼ tuberculosis.

patients with asymptomatic left ventricular
dysfunction. From a health-system perspective, the
experts suggested formulating multi-country registries and national databases through electronic records for collection of relevant data that can
appropriately gauge the region-speciﬁc needs and
practices in MEA (Table 2).
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5. Evidence supporting strategic
recommendations
5.1. Enhance patient awareness
The experts agreed unanimously that enhanced
patient awareness regarding prevention is the

Table 2. Provider/health-system level recommendations for enhanced awareness and prevention of HF.
Training for
enhancing
awareness and
knowledge

Prevention and
strategic
management

Multidisciplinary
care and task
sharing

Data generation

Collaborative
stakeholder
partnership

Provider-related Recommendations

Health System-related Recommendations

 Train healthcare professionals through outreach
programs and disseminate the national HF management guidelines
 Educate physicians for compliance to guidelinedirected medication
 Raise awareness to ensure clinicians prescribe evidence-based therapy and titrate the dose to the
target dose
 Focus on prevention of HF by early identiﬁcation
patients at high risk such as those with hypertension and ischemic heart disease
 Enhance concordance to guideline recommended
therapy
 Focus on optimal management of comorbidities
like CVD, CKD, and T2DM and associated
mortality
 Enhance shared-decision making with patients
 Involve nurses in the care of HF
 Conduct exchange training programs of nurses
across the region for improving management,
whilst mitigating language barriers
 Encourage nurses and paramedics to engage in
specialized HF care and patient support
 Adopt MDT approach for HF management. The
beneﬁt can be immediate compared to HF clinics,
which would require long time and high economic
investments.
 Increase HF clinics
 Publish guidelines and call to action paper to
create awareness among the cardiologists about
HFpEF including phenotypes like amyloidosis
 Adopt innovative solutions for patient support
such as follow-ups on a virtual platform to support
HF management during pandemic times

 Prioritizing HF alongside other infectious diseases
 Create local HF societies to educate physicians
 Improve access and insurance for novel therapies
like SGLT2 inhibitor for primary prevention of HF

 Prevent HF progression by optimal use and reimbursement of drugs that inﬂuence the course of HF
such as SGLT2i, beta-blockers, RAASi, and ARNI

 Focus on primary healthcare centers for early
detection and referral of patients
 Improved access to care and follow-up through
pooled sourcing, quality generic medications and
targeted efforts for local manufacturing

 Initiate a structured approach to provide access to
patients with HF
 Develop centers for excellence for diagnosis of
HFpEF

 Initiate registries to increase the collection of relevant data through electronic records, and national
databases
 Generate country-speciﬁc unmet needs and recommendations for HF management focussing on
clinical inertia and challenges with timely uptitration of doses
 Develop local registries to give insights on HF
management covering urban and rural areas
 Initiate registry for the MEA region to generate
robust region-speciﬁc database providing realworld insights on gaps and treatment patterns
 Identify key partners from each country to solicit
collaborative care and facilitate program
implementation
 Engage stakeholders to pave the way for novel
therapies and new research activities, focusing on
funding
 Include HF in healthcare reforms in collaboration
with health authorities
 Involve policymakers for reimbursement resources

ARNI ¼ angiotensin receptor II blocker - neprilysin inhibitor; CKD ¼ chronic Kidney disease; CVD ¼ cardiovascular disease; HF ¼ heart
failure; T2DM ¼ type 2 diabetes mellitus; SGLT2 inhibitors ¼ sodium-glucose cotransporter-2 inhibitors; MDT ¼ multidisciplinary team;
HFpEF ¼ heart failure with preserved ejection fraction; RAASi ¼ renin-angiotensinealdosterone system inhibitors.

ORIGINAL ARTICLE

JOURNAL OF THE SAUDI HEART ASSOCIATION 2022;34:53e65

58

JOURNAL OF THE SAUDI HEART ASSOCIATION 2022;34:53e65

ORIGINAL ARTICLE

foundation stone for HF care. Maintaining optimum
body weight, smoking cessation, alcohol intake restriction, regular exercise, heathy diet, and cholesterol reduction are associated with a lower lifetime
risk of HF [20]. The World Heart Federation “heart
failure gap review” estimated that globally 55% of
people did not recognise a description of HF and
67% underestimated conditions such as diabetes,
high blood pressure, and coronary heart disease as
the leading risk factors for developing HF [21].
Despite a high burden of risk factors in Middle East
and North Africa (MENA), the control of hypertension and dyslipidaemia is sub-optimald70% of low
income subjects had dyslipidaemia but only 4%
were taking lipid-lowering medication [22,23]. This
necessitates raising awareness for prevention
through combined healthy lifestyle factors, particularly in the younger population due to the early age
of HF onset in the region. Providing patient support
by telecommunication-based education activities,
leveraging digital technology such as smartphone
applications, text messaging and social media campaigns, can effectively overcome barriers of access
in a timely and cost-effective manner [24].
5.2. Enhance physician and provider knowledge
The experts acknowledged the need for enhancing
physician and provider knowledge for recognising
patients at risk of developing HF, symptom recognition, referral processes and treatment algorithms.
Empowering nonphysician health-care workers
such as nurses, pharmacists, or community-health
workers to facilitate task shifting/sharing in limited
resource settings can help eliminate the trade-offs
between health-care accessibility and availability,
thus effectively managing blood pressure and risk
modiﬁcation [25e27]. A study from rural Rwanda,
Africa reported that nurse performed echocardiography had high sensitivity and speciﬁcity for mitral
stenosis, hypertensive heart disease and isolated
right HF. The study further demonstrated that patients had a signiﬁcant improvement in NYHA class
(P<.0001) over 10 years [28]. Gaps in physician
adherence to guidelines can be explained by factors
such as clinical inertia. A study focusing on interventions such as (1) health information technology; (2) optimising teamwork; and (3) providing
education to patients and physicians, reported a
reduction in the number of emergency department
visits and hospital admissions [29]. Provider-level
interventions encompassing audit and feedback,
reminders, alongside enhanced medical records
system, multidisciplinary teams, and continuity of

care can be instrumental in increasing concordance
to guideline uptake [30].
5.3. Development of robust real-world databases
and registries
The majority of the panel were very keen to
establish a robust database including electronic
health records and registries to gain precise insights
on real-world challenges for HF in the MEA region.
According to the World Heart Federation review,
only 12% of policymakers recognised HF as the
leading cause of avoidable hospitalisations and 42%
prioritised prevention [21]. Long-term prospective
registries of HF can provide unique opportunities to
assess disease burden, characterisation of risk factors, treatment patterns, gaps in clinical practice and
outcomesd providing a comparative platform
across different regions. Robust registries including
larger populations can contribute to an ongoing
quality assurance, indicating areas of improvement
such as patient non-adherence, physicians' nonconcordance to recommendations, voids in medical
training or patient educationd constituting a reliable, invaluable tool to guide routine clinical practice. Standardised national level registries can
compare the disease management between several
different countries, and provide benchmark estimates of mortality, morbidity and resource utilisation [31,32]. Although few registries such as the
heart function assessment registry trial (HEARTS)
from Saudi Arabia, Egyptian cohort of European
Society of Cardiology Heart Failure Long-Term
registry, Oman Acute Heart Failure Registry, Gulf
CARE in 7 Middle Eastern countries and Program
for the Evaluation and Management of the Cardiac
Events (PEACE) MENA have set the foundation,
well-designed national multicentre registries
exploring sub-population with multiple morbidities,
geriatric age group or from different ethnicities,
across the disease spectrum, are further needed to
reinforce and validate real-world data for the MEA
region [11,12,33e36].
5.4. Pharmacotherapy for HF prevention
Major registries from the MEA region have revealed
a high burden (nearly 50%) of type 2 diabetes mellitus,
hypertension, or hypercholesterolaemia. As patients
with these modiﬁable risk factors have a multifold risk
for cardiovascular diseases (with HF becoming the
major presentation of cardiovascular disease),
aggressive implementation of evidence-based management through lifestyle and pharmacological

interventions should be at the core of HF prevention.
Based on the pleiotropic beneﬁt of novel therapies for
prevention of major adverse cardiovascular events
(MACE; cardiovascular death, nonfatal myocardial
infarction, nonfatal stroke), reduction in HF hospitalisations and renal end points, recent evidence
recommend utilisation of sodium-glucose co-transporter-2 inhibitor or glucagon-like peptide-1 receptor
agonist to reduce HF risk in patients with diabetes
[37e41]. Heart Failure Association of the European
Society of Cardiology expert consensus (2019) recommends that canagliﬂozin and dapagliﬂozin should
also be considered for patients with type 2 diabetes
mellitus and either established cardiovascular disease
or at high cardiovascular risk, in order to prevent or
delay the onset of and hospitalisations for HF [42].
Similar to diabetes, hypertension management is
pivotal to prevent HF. The Systolic Blood Pressure
Intervention Trial (SPRINT) reported that intensive
blood pressure control may be one of the most effective ways to delay the onset of HF [43]. There is
reasonable evidence that statins can reduce the rate of
cardiovascular events and thus prevent or delay the
onset of HF [44,45]. Timely and optimal care management tailored to patient status and comorbidities
through novel therapies such as beta-blockers,
angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonists, sodiumglucose co-transporter-2 inhibitors, vasodilators, or
ivabradine can be crucial to improve patient outcomes
across the spectrum of HF [37,46,47]. Although professional guidelines recommend sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide-1 receptor agonist therapy for the primary beneﬁt of cardiovascular risk management, their widespread
utilisation is low, even for “at risk” patients with diabetes and clinical manifestations of cardiovascular
disease [48]. Despite cardiologists being well-positioned to improve access to these cardioprotective
drugs, lack of familiarity with the therapies and
perception that management of diabetes is beyond
their scope, hinder adequate prescription [49,50].
Formulation of treatment pathways that simplify
prescribing, educational programmes for clinicians
and patients, along with coordinated models of care
can pave the way for bridging this gap [51].

6. Gaps and recommendations to enhance the
efﬁciency of HF diagnosis
The experts discussed that a complicated diagnostic pathway, inadequate guidelines and practice
of referral, as well as scarcity of trained healthcare

59

workers can hinder the effective diagnosis and
management of HF. Low utilisation of biomarkers
such as N-terminal pro b -type natriuretic peptide
(NT proBNP), because of even scarcer availability
of echocardiography, can further compound a
delayed or missed diagnosis. As HF is a complex
disease (especially the HFpEF population), lack of
expert participation in verifying the diagnosis of
HF can create ambiguities in risk detection and
subsequent delayed diagnosis. The experts discussed that formulation of simple region-speciﬁc
diagnostic algorithms to identify HF and efﬁcient
referral mechanism at different tiers of health-care
can be fundamental to improve diagnosis.
Improving access and availability of essential diagnostics including cardiac echocardiography and
engaging in discussions with policymakers for
reimbursement can enhance diagnosis. Multidisciplinary care teams and development of centres
for excellence to guide early referral in tertiary
centres, along with creation of HF clinics can
facilitate early diagnosis (Table 3). Creation of
credible and dedicated HF task force can help
establish HF clinics in hospitals, thus streamlining
clear operation policies and standardised health
care system.

7. Evidence supporting strategic
recommendations
7.1. Screening and early detection of patients with
heart failure
Algorithms such as the WATCH-DM (Weight
[body mass index], Age, hypertension, Creatinine,
high density lipoprotein cholesterol, Diabetes
control [fasting plasma glucose], QRS Duration,
Myocardial Infarction, and Coronary Artery Bypass
Grafting) risk score can facilitate risk prediction of
incident HF among patients with diabetes based on
machine learning [52]. Similarly, the novel
Thrombolysis in Myocardial Infarction risk score
can facilitate risk stratiﬁcation in patients with
diabetesdidentifying those at higher risk for HF
and those who can derive greater absolute beneﬁt
from the therapeutic management [53]. Timely
diagnosis of HF is critical, but identiﬁcation of
patients with suspected HF can be challenging,
especially in primary care. The recently published
universal deﬁnition describes HF as a clinical
syndrome with current or prior symptoms and or
signs caused by a structural and/or functional
cardiac abnormality (as determined by ejection
fraction <50%, abnormal cardiac chamber enlarge-
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Table 3. Barriers and strategic recommendations for diagnosis of heart failure.
Barriers

Recommendations

Complicated diagnostic pathway for HF
Underutilization of diagnostics and failure to perform imaging
techniques due to scarcity of trained healthcare workers
Missed diagnosis due to inadequate referral

Formulation of simple diagnosis algorithms to identify HF
Improve access to advanced diagnostics and train primary care
health workers for ECG and echocardiography ultrasound
 Formulation of region-speciﬁc efﬁcient referral mechanism at
different tiers of healthcare
 Adequate follow-up of patients in the general cardiology clinic
 Improved access and training
 Develop centers for excellence for biomarkers and ECG to
guide early referral in tertiary centers
Formulation of multidisciplinary teams
Dedicated HF clinics with dedicated resources such as nurses for
early detection
Engage with policy makers for reimbursement resources to help
the patients ﬁnancially
Engage policymakers in HF for awareness campaigns and clinical decision-making

Lack of knowledge, poor access, high cost, and corresponding
low utilization of biomarkers such as Pro-NT-BNP
Lack of expert participation in verifying the diagnosis of HF
Lack of HF clinics and lack of dedicated patient-centric HF
programs
Poor access and affordability to health facilities to diagnose HF
Financial barriers in some countries where NTproBNP is not
reimbursed by third-party payers

ECG ¼ electrocardiogram; HF ¼ heart failure; Pro-NT-BNP]N-terminal pro b-type natriuretic peptide.

ment, E/E’>15, moderate/severe ventricular hypertrophy or moderate/severe valvular obstructive
or regurgitant lesion) and corroborated by at least
one of the following: elevated natriuretic peptide
levels or objective evidence of cardiogenic pulmonary or systemic congestion by diagnostic modalities such as imaging or haemodynamic
measurement at rest or with provocation [54].
Though natriuretic peptides are currently not recommended as a screening tool for general population in the MEA region, its screening in high risk
patients (especially patients with type 2 diabetes
mellitus) can be helpful in preventing HF [55].
Guidelines recommend natriuretic peptide blood
test for people presenting to primary care with
suspected HF and subsequent referral for echocardiography and specialist assessment if the level
is raised [46,56,57]. However, patients might follow
diverse diagnostic pathways, which may or may
not be aligned with the guidelines for investigation
and referraldleading to missed opportunities for
early HF diagnosis in primary care [58,59]. Adoption of simple and unambiguous diagnosis algorithms to identify HF (using the basic 12-lead
electrocardiogram and a chest X-Ray), alongside
enhanced access to advanced imaging modalities
(echocardiography) and trained healthcare providers can drive early detection of HF [60]. A
normal 12-lead electrocardiogram almost excludes
a HFrEF diagnosis. The World Heart Federation
Roadmap for HF illustrated a clear continuum for
care pathway beginning with risk factor screening,
culminating in the end of life care [61]. Adaptation
of such pathways based on the region-speciﬁc
characteristics can be instrumental in enhanced
diagnosis of HF.

7.2. Multidisciplinary team approach to heart
failure care
The experts highlighted fragmented care as the
major barrier in HF management. Given the multifaceted aetiology of HF, a multidisciplinary team
approach is considered the gold standard model for
optimal care. The National Institute for Health and
Care Excellence (NICE) guidelines recommend a
multidisciplinary team including a core specialist
working in collaboration with the primary care team
(lead physician with subspecialty training in heart
failure who is responsible for making the clinical
diagnosis), a specialist HF nurse and a healthcare
professional with expertise in prescribing for HF
[56]. Other multidisciplinary team members may
also include pharmacist, physiotherapist, palliative
care, psychologist, or occupational therapist and
administrator. Beneﬁts of multidisciplinary team
approach include engagement of health professionals across health care sectors, implementation of evidence-based management guidelines,
monitoring of signs and symptoms for early identiﬁcation of decompensation and/or deterioration,
and effective protocols for symptom management.
Multidisciplinary team further fosters involvement
of patients and their families for care planning,
development and implementation of individualised
management plans for self-care. A growing body of
evidence has shown improved patient outcomes
with signiﬁcant reductions in mortality and/or allcause and HF hospitalisations through multidisciplinary team care [62,63]. Although a multidisciplinary team approach is ideal, it might be
challenging in many countries of the MEA region at
this stage. Hence, the members should be selected

depending on country-speciﬁc resources, primarily
a HF nurse and physician with HF care experience.
Local clinics with educated nurses who can
communicate with a central hub having electrocardiogram, chest X-Ray and blood review via telemedicine, might also be a reasonable aim for the
low- and middle-income countries countries.
7.3. Heart failure clinics based on hub-and-spoke
model of integrated care
The experts advocated the development of HF
clinics and emphasised on the crucial role of nurses
for driving optimal HF care. Similar thoughts were
echoed by cardiologists’ who suggested implementation of a structured, patient-centered, and
ﬂexible model of disease management programme,
along with integrated data approaches [64]. In
comparison to general cardiology out-patient
department, dedicated HF clinics were better in
maintaining guideline-directed medication therapy,
together with decreased rate of rehospitalisation
and mortality [65,66]. A study from Saudi Arabia
showed that a structured HF programme can
signiﬁcantly enhance quality of life and dramatically
decline hospital admissions [67]. Nurse-led HF
clinics can help early diagnosis in economically and
socially vulnerable patients with advanced cardiovascular disease and facilitate initiation of guideline-directed therapy before seeing a specialist
[28,68]. However, majority countries in the MEA
region either do not have nurse practitioners or they
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are ineligible to prescribe the drugs. Considering
the shortage of skilled resources and the extent of
economic burden on healthcare systems in MEA
[69], development of HF clinics based on the hub
and spoke model of integrated care can be promising. Network of HF clinics with a multidisciplinary
team of experts as the hub d offering full array of
services, complemented by a network of primary
care sector (spokes) d offering limited service for
low-risk patients, while routing patients needing
more intensive services to the hub for treatment, can
potentially lead to better patient outcomes [70,71]
(Fig. 3). In the MEA region, this would mostly apply
to the larger cities that are better resourced. Peripheral and rural areas have signiﬁcant challenges,
wherein valvular heart disease may have a greater
signiﬁcance. Establishing effective screening and
management of HF in these areas remain a signiﬁcant challenge.

8. Way forward
Despite the heavy burden of HF in MEA, there are
signiﬁcant pitfalls in the arena of research and
development. In addition, the policy initiatives are
also limited. It is imperative for policy makers,
healthcare
professionals
and
administrative
personnel to identify the strategic importance and
prioritise HF at a national level through concerted
efforts. Greater representation of MEA region in
global studies and clinical trials is crucial to counter
the signiﬁcant under representation in large

Fig. 3. Hub and spoke model for integrated heart failure care. HF ¼ heart failure.
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randomised HF studies. Developing a HF national
roadmap for comprehensive primary prevention
strategies, establishing patient advocacy groups,
strong intersectoral policies, engaging professional
societies and public health authorities is central to
creating a sustainable health system [72]. Development of regional or national guidelines factoring in
the local challenges and roadblocks can be instrumental in driving HF care. In addition, use of
innovative tools, telemedicine and digital technology, such as artiﬁcial intelligence, for predicting
diagnosis can be favourable, particularly where inperson representation is not feasible. In addition,
commitment for adequate funding and reimbursement is pivotal for overcoming structural and
health-system related barriers in the MEA region.
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9. Conclusion

AB, HS, HA, KA, KA, RT have no conﬂict of interest to disclose. EO received honorarium for lectures, presentations, speaker bureaus from Astra
Zeneca, Bayer, and Novartis. EK received speaker
honorarium, travel assistance (Astra Zeneca, Servier, Novartis) and has been the head of ethics and
guideline committee, SA heart. HR received honoraria for lectures from Novartis, BI, AstraZeneca,
MSD & Sanoﬁ. MA received speaker honoraria from
Bayer, Novartis, Boehringer-Ingelheim & Astra
Zeneca. MY received Institutional fee from Novartis,
Bayer, Amgen, Astra Zeneca. YÇ received honorarium for lectures or educational events from Astra
Zeneca, Servier, Novartis, Roche Diagnostics, Sanoﬁ
Aventis, Otsuka Pharmaceuticals, Actelion, Bayer.

There are wide gaps and unmet needs in awareness, prevention, and diagnosis of HF in the MEA
region. Enhancing patient awareness with emphasis
on prevention through digital methods or social
media campaigns, alongside raising awareness of
providers and policy makers with streamlined
training programs and referral process, can address
deﬁciencies in knowledge for HF care. Utilisation of
guideline-recommended pharmacotherapy such as
sodium-glucose co-transporter-2 inhibitors for primary prevention of HF in at-risk patients with diabetes can support pleotropic effect in high-risk
populations. Focusing on a multidisciplinary
approach to care while ensuring concordance to
evidence-based therapy can be crucial. Comprehensive real-world data collection through welldesigned multicentre registries and widespread
establishment of HF clinics encompassing expanded
role of nurses can potentially drive the momentum
of HF care across all tiers of healthcare in MEA.
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